Current Psychiatry Reports

, Volume 6, Issue 4, pp 283–288 | Cite as

Patient and family attitudes toward schizophrenia treatment

  • Farzin Irani
  • Mary Dankert
  • Steven J. Siegel


Patient and family member attitudes toward illness, psychopharmacologic and nonpharmacologic treatments in schizophrenia, as well as their attitudes toward psychiatric research are reviewed here. The authors’ recent work investigating patient and family member attitudes toward illness, medication, and a new method of receiving medication via surgical implants is also presented. The authors highlight the importance of understanding patient attitudes so that individual treatment plans and new treatments for schizophrenia can be facilitated. The important contribution of family members in caring for their loved ones is also emphasized. Patient participation in biomedical research is also discussed in the context of guiding the treatment of schizophrenia.


Schizophrenia Clozapine Aripiprazole Schizophrenia Patient Psychiatric Medication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Navon L, Ozer N: Ordinary logic in unordinary lay theories: a key to understanding proneness to medication nonadherence in schizophrenia. Arch Psychiatr Nurs 2003, 17:108–116.PubMedCrossRefGoogle Scholar
  2. 2.
    Stark FM, Stolle R: [Schizophrenia: subjective illness theories-an explorative study. 1: patients]. Psychiatr Prax 1994, 21:74–78.PubMedGoogle Scholar
  3. 3.
    Ullrich J, Ulmar G, Starzinski T: [Disease models and change in attitude of involuntarily admitted schizophrenic patients]. Fortschr Neurol Psychiatr 1995, 63:480–486.PubMedCrossRefGoogle Scholar
  4. 4.
    Larsen EB, Gerlach J: Subjective experience of treatment, sideeffects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand 1996, 93:381–388.PubMedGoogle Scholar
  5. 5.
    Poulsen HD, Engberg M: Validation of psychiatric patients’ statements on coercive measures. Acta Psychiatr Scand 2001, 103:60–65.PubMedCrossRefGoogle Scholar
  6. 6.
    Irani F, Dankert M, Brensinger C, et al.: Patient attitude towards surgically implantable, long-term delivery of psychiatric medicine. Neuropsychopharmacology 2004, 29:960–968. Decribes patients’ attitudes toward a novel treatment for mental illness.PubMedCrossRefGoogle Scholar
  7. 7.
    Jungbauer J, Wittmund B, Dietrich S, Angermeyer MC: Subjective burden over 12 months in parents of patients with schizophrenia. Arch Psychiatr Nurs 2003, 17:126–134.PubMedCrossRefGoogle Scholar
  8. 8.
    North CS, Pollio DE, Sachar B, et al.: The family as caregiver: a group psychoeducation model for schizophrenia. Am J Orthopsychiatry 1998, 68:39–46.PubMedCrossRefGoogle Scholar
  9. 9.
    Dyck DG, Short R, Vitaliano PP: Predictors of burden and infectious illness in schizophrenia caregivers. Psychosom Med 1999, 61:411–419.PubMedGoogle Scholar
  10. 10.
    McDonell MG, Short RA, Berry CM, Dyck DG: Burden in schizophrenia caregivers: impact of family psychoeducation and awareness of patient suicidality. Fam Process 2003, 42:91–103.PubMedCrossRefGoogle Scholar
  11. 11.
    Schulz PM, Schulz SC, Dibble E, et al.: Patient and family attitudes about schizophrenia: implications for genetic counseling. Schizophr Bull 1982, 8:504–513.PubMedGoogle Scholar
  12. 12.
    Angermeyer MC, Matschinger H: The effect of personal experience with mental illness on the attitude towards individuals suffering from mental disorders. Soc Psychiatry Psychiatr Epidemiol 1996, 31:321–326.PubMedCrossRefGoogle Scholar
  13. 13.
    Kampman O, Lehtinen K, Lassila V, et al.: Attitudes towards neuroleptic treatment: reliability and validity of the attitudes towards neuroleptic treatment (ANT) questionnaire. Schizophr Res 2000, 45:223–234.PubMedCrossRefGoogle Scholar
  14. 14.
    Hogan TP, Awad AG, Eastwood R: A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983, 13:177–183.PubMedCrossRefGoogle Scholar
  15. 15.
    Naber D, Moritz S, Lambert M, et al.: Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001, 50:79–88.PubMedCrossRefGoogle Scholar
  16. 16.
    Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24:67–74.PubMedCrossRefGoogle Scholar
  17. 17.
    Hellewell JS: Patients’ subjective experiences of antipsychotics: clinical relevance. CNS Drugs 2002, 16:457–471. Describes patients’ attitudes toward depot antipsychotic treatment.PubMedCrossRefGoogle Scholar
  18. 18.
    Castle D, Morgan V, Jablensky A: Antipsychotic use in Australia: the patients’ perspective. Aust N Z J Psychiatry 2002, 36:633–641.PubMedCrossRefGoogle Scholar
  19. 19.
    Leucht S, Wahlbeck K, Hamann J, Kissling W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003, 361:1581–1589.PubMedCrossRefGoogle Scholar
  20. 20.
    Gerlach J, Larsen EB: Subjective experience and mental sideeffects of antipsychotic treatment. Acta Psychiatr Scand Suppl 1999, 395:113–117.PubMedGoogle Scholar
  21. 21.
    Sajatovic M, Rosch DS, Sivec HJ, et al.: Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatr Serv 2002, 53:1319–1321.PubMedCrossRefGoogle Scholar
  22. 22.
    Garavan J, Browne S, Gervin M, et al.: Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics: attitudes to medication and insight. Compr Psychiatry 1998, 39:215–219.PubMedCrossRefGoogle Scholar
  23. 23.
    Hofer A, Kemmler G, Eder U, et al.: Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 2002, 63:49–53.PubMedGoogle Scholar
  24. 24.
    Angermeyer MC, Matschinger H: [Attitude of family to neuroleptics]. Psychiatr Prax 1999, 26:171–174.PubMedGoogle Scholar
  25. 25.
    Angermeyer MC, Boitz K, Loffler W, et al.: [Attitude of family to clozapine]. Psychiatr Prax 1999, 26:181–187.PubMedGoogle Scholar
  26. 26.
    Walburn J, Gray R, Gournay K, et al.: Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001, 179:300–307.PubMedCrossRefGoogle Scholar
  27. 27.
    Svedberg B, Backenroth-Ohsako G, Lutzen K: On the path to recovery: patients’ experiences of treatment with long-acting injections of antipsychotic medication. Int J Ment Health Nurs 2003, 12:110–118.PubMedCrossRefGoogle Scholar
  28. 28.
    Patel MX, Nikolaou V, David AS: Psychiatrists’ attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003, 33:83–89.PubMedCrossRefGoogle Scholar
  29. 29.
    Judge R: Patient perspectives on once-weekly fluoxetine. J Clin Psychiatry 2001, 62(suppl):53–57.PubMedGoogle Scholar
  30. 30.
    Siegel SJ, Winey KI, Gur RE, et al.: Surgically implantable longterm antipsychotic delivery systems for the treatment of schizophrenia. Neuropsychopharmacology 2002, 26:817–823. Describes surgically implantable antipsychotic delivery systems.PubMedCrossRefGoogle Scholar
  31. 31.
    Pekkala E, Merinder L: Psychoeducation for schizophrenia. Cochrane Database Syst Rev 2002, CD002831.Google Scholar
  32. 32.
    Hayashi N, Yamashina M, Igarashi Y, Kazamatsuri H: Improvement of patient attitude toward treatment among inpatients with schizophrenia and its related factors: controlled study of a psychological approach. Compr Psychiatry 2001, 42:240–246.PubMedCrossRefGoogle Scholar
  33. 33.
    Hofer E, Wancata J, Amering M: #x201C;I am a Misunderstood Being on Earth.#x201D; Concept of illness of patients suffering from schizophrenic psychosis before and after psychoeducational treatment]. Psychiatr Prax 2001, 28:287–291.PubMedCrossRefGoogle Scholar
  34. 34.
    Angermeyer MC, Held T, Gortler D: [Pro and contra: psychotherapy and psychopharmacotherapy attitude of the public]. Psychother Psychosom Med Psychol 1993, 43:286–292.PubMedGoogle Scholar
  35. 35.
    Angermeyer MC, Matschinger H: Public attitude towards psychiatric treatment. Acta Psychiatr Scand 1996, 94:326–336.PubMedGoogle Scholar
  36. 36.
    Carpenter WT Jr., Gold JM, Lahti AC, et al.: Decisional capacity for informed consent in schizophrenia research. Arch Gen Psychiatry 2000, 57:533–538. Describes patients’ capacity for providing informed consent to participate in biomedical research.PubMedCrossRefGoogle Scholar
  37. 37.
    Roberts LW, Warner TD, Nguyen KD, et al.: Schizophrenia patients’ and psychiatrists’ perspectives on ethical aspects of symptom re-emergence during psychopharmacological research participation. Psychopharmacology (Berl) 2003, 171:58–67.CrossRefGoogle Scholar
  38. 38.
    Roberts LW, Warner TD, Brody JL: Perspectives of patients with schizophrenia and psychiatrists regarding ethically important aspects of research participation. Am J Psychiatry 2000, 157:67–74.PubMedGoogle Scholar
  39. 39.
    Hummer M, Holzmeister R, Kemmler G, et al.: Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. J Clin Psychiatry 2003, 64:277–281.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Farzin Irani
  • Mary Dankert
  • Steven J. Siegel
    • 1
  1. 1.Division of NeuropsychiatryUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations